APO Research
Talk to an analyst

APO RESEARCH · REPORT

First in Class (FIC) Antibody Drug Conjugate (ADC)

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Growth and Trends Forecast to 2032

23 December 2025123 pages

Choose your research edition.

Industry ResearchFirst in Class (FIC) Antibody Drug Conjugate (ADC) Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal First in Class (FIC) Antibody Drug Conjugate (ADC) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal First in Class (FIC) Antibody Drug Conjugate (ADC) Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal First in Class (FIC) Antibody Drug Conjugate (ADC) Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global First in Class (FIC) Antibody Drug Conjugate (ADC) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for First in Class (FIC) Antibody Drug Conjugate (ADC) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for First in Class (FIC) Antibody Drug Conjugate (ADC) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for First in Class (FIC) Antibody Drug Conjugate (ADC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of First in Class (FIC) Antibody Drug Conjugate (ADC) include Arvinas, Bayer Corporation, Bicara Therapeutics, Fabhalta, Immatics, Litfulo, Lytgobi, Merus and Ogsiveo, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global First in Class (FIC) Antibody Drug Conjugate (ADC) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The First in Class (FIC) Antibody Drug Conjugate (ADC) market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global First in Class (FIC) Antibody Drug Conjugate (ADC) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to First in Class (FIC) Antibody Drug Conjugate (ADC).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global First in Class (FIC) Antibody Drug Conjugate (ADC) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

First in Class (FIC) Antibody Drug Conjugate (ADC) Market by Company

Arvinas

Bayer Corporation

Bicara Therapeutics

Fabhalta

Immatics

Litfulo

Lytgobi

Merus

Ogsiveo

Pumis Biotechnology (BioNTech)

Regeneron Pharmaceuticals

Skyclary

Talvey

Telix

Truqap

Vertex Pharmaceuticals

AstraZeneca

Dizal Pharma

Shanghai Henlius Biotech, Inc.

GSK

Jiangsu Hengrui Medicine

Pfizer

Akeso, Inc

Lixin Pharmaceutical Technology

Johnson & Johnson

Beijing Hotgen Biotech

Suzhou Yilian Biopharmaceutical

Shenzhen Yipusheng

Foreseen Biotechnology

Suzhou Zejing Biopharmaceutical

First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Type

Small Molecule FIC Drugs

Large Molecule FIC Drugs

First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Application

Tumors and Cancers

Others

First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global First in Class (FIC) Antibody Drug Conjugate (ADC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of First in Class (FIC) Antibody Drug Conjugate (ADC) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of First in Class (FIC) Antibody Drug Conjugate (ADC).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of First in Class (FIC) Antibody Drug Conjugate (ADC) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of First in Class (FIC) Antibody Drug Conjugate (ADC) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Small Molecule FIC Drugs Table 2. Major Company of Large Molecule FIC Drugs Table 3. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2026) & (k units) Table 5. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Volume by Type (2021-2026) Table 6. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2026) & (US$ Million) Table 7. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Value by Type (2021-2026) Table 8. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price by Type (2021-2026) & (USD/unit) Table 9. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2027-2032) & (k units) Table 10. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Volume by Type (2027-2032) Table 11. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2027-2032) & (US$ Million) Table 12. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Value by Type (2027-2032) Table 13. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price by Type (2027-2032) & (USD/unit) Table 14. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2026) & (k units) Table 15. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2026) & (US$ Million) Table 16. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2026) & (k units) Table 17. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2026) & (k units) Table 21. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (2021-2026) & (US$ Million) Table 24. First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Trends Table 25. First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Drivers Table 26. First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Opportunities and Challenges Table 27. First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Restraints Table 28. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Company (2021-2026) Table 30. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Company (2021-2026) & (k units) Table 31. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Share by Company (2021-2026) Table 32. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Price by Company (2021-2026) & (USD/unit) Table 33. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Major Company Production Sites and Headquarters Table 35. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Company, Product Type & Application Table 36. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global First in Class (FIC) Antibody Drug Conjugate (ADC) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2021-2026) & (k units) Table 41. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Volume by Region (2021-2026) Table 42. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2021-2026) & (US$ Million) Table 43. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Value by Region (2021-2026) Table 44. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 45. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2027-2032) & (k units) Table 46. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Volume by Region (2027-2032) Table 47. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2027-2032) & (US$ Million) Table 48. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Value by Region (2027-2032) Table 49. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2027-2032) Table 50. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2026) & (k units) Table 52. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Volume by Application (2021-2026) Table 53. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2026) & (US$ Million) Table 54. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Value by Application (2021-2026) Table 55. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price by Application (2021-2026) & (USD/unit) Table 56. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2027-2032) & (k units) Table 57. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Volume by Application (2027-2032) Table 58. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2027-2032) & (US$ Million) Table 59. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Value by Application (2027-2032) Table 60. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price by Application (2027-2032) & (USD/unit) Table 61. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2026) & (k units) Table 62. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2026) & (US$ Million) Table 63. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2026) & (k units) Table 64. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2026) & (k units) Table 68. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2021-2026) & (US$ Million) Table 71. Arvinas Company Information Table 72. Arvinas Business Overview Table 73. Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 74. Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 75. Arvinas Recent Development Table 76. Bayer Corporation Company Information Table 77. Bayer Corporation Business Overview Table 78. Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 79. Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 80. Bayer Corporation Recent Development Table 81. Bicara Therapeutics Company Information Table 82. Bicara Therapeutics Business Overview Table 83. Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 84. Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 85. Bicara Therapeutics Recent Development Table 86. Fabhalta Company Information Table 87. Fabhalta Business Overview Table 88. Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 90. Fabhalta Recent Development Table 91. Immatics Company Information Table 92. Immatics Business Overview Table 93. Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 95. Immatics Recent Development Table 96. Litfulo Company Information Table 97. Litfulo Business Overview Table 98. Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 100. Litfulo Recent Development Table 101. Lytgobi Company Information Table 102. Lytgobi Business Overview Table 103. Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 105. Lytgobi Recent Development Table 106. Merus Company Information Table 107. Merus Business Overview Table 108. Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 110. Merus Recent Development Table 111. Ogsiveo Company Information Table 112. Ogsiveo Business Overview Table 113. Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 115. Ogsiveo Recent Development Table 116. Pumis Biotechnology (BioNTech) Company Information Table 117. Pumis Biotechnology (BioNTech) Business Overview Table 118. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 120. Pumis Biotechnology (BioNTech) Recent Development Table 121. Regeneron Pharmaceuticals Company Information Table 122. Regeneron Pharmaceuticals Business Overview Table 123. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 125. Regeneron Pharmaceuticals Recent Development Table 126. Skyclary Company Information Table 127. Skyclary Business Overview Table 128. Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 130. Skyclary Recent Development Table 131. Talvey Company Information Table 132. Talvey Business Overview Table 133. Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 135. Talvey Recent Development Table 136. Telix Company Information Table 137. Telix Business Overview Table 138. Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 140. Telix Recent Development Table 141. Truqap Company Information Table 142. Truqap Business Overview Table 143. Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 144. Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 145. Truqap Recent Development Table 146. Vertex Pharmaceuticals Company Information Table 147. Vertex Pharmaceuticals Business Overview Table 148. Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 149. Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 150. Vertex Pharmaceuticals Recent Development Table 151. AstraZeneca Company Information Table 152. AstraZeneca Business Overview Table 153. AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 154. AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 155. AstraZeneca Recent Development Table 156. Dizal Pharma Company Information Table 157. Dizal Pharma Business Overview Table 158. Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 159. Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 160. Dizal Pharma Recent Development Table 161. Shanghai Henlius Biotech, Inc. Company Information Table 162. Shanghai Henlius Biotech, Inc. Business Overview Table 163. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 164. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 165. Shanghai Henlius Biotech, Inc. Recent Development Table 166. GSK Company Information Table 167. GSK Business Overview Table 168. GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 169. GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 170. GSK Recent Development Table 171. Jiangsu Hengrui Medicine Company Information Table 172. Jiangsu Hengrui Medicine Business Overview Table 173. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 174. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 175. Jiangsu Hengrui Medicine Recent Development Table 176. Pfizer Company Information Table 177. Pfizer Business Overview Table 178. Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 179. Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 180. Pfizer Recent Development Table 181. Akeso, Inc Company Information Table 182. Akeso, Inc Business Overview Table 183. Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 184. Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 185. Akeso, Inc Recent Development Table 186. Lixin Pharmaceutical Technology Company Information Table 187. Lixin Pharmaceutical Technology Business Overview Table 188. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 189. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 190. Lixin Pharmaceutical Technology Recent Development Table 191. Johnson & Johnson Company Information Table 192. Johnson & Johnson Business Overview Table 193. Johnson & Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 194. Johnson & Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 195. Johnson & Johnson Recent Development Table 196. Beijing Hotgen Biotech Company Information Table 197. Beijing Hotgen Biotech Business Overview Table 198. Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 199. Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 200. Beijing Hotgen Biotech Recent Development Table 201. Suzhou Yilian Biopharmaceutical Company Information Table 202. Suzhou Yilian Biopharmaceutical Business Overview Table 203. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 204. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 205. Suzhou Yilian Biopharmaceutical Recent Development Table 206. Shenzhen Yipusheng Company Information Table 207. Shenzhen Yipusheng Business Overview Table 208. Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 209. Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 210. Shenzhen Yipusheng Recent Development Table 211. Foreseen Biotechnology Company Information Table 212. Foreseen Biotechnology Business Overview Table 213. Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 214. Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 215. Foreseen Biotechnology Recent Development Table 216. Suzhou Zejing Biopharmaceutical Company Information Table 217. Suzhou Zejing Biopharmaceutical Business Overview Table 218. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 219. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio Table 220. Suzhou Zejing Biopharmaceutical Recent Development Table 221. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 222. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026) & (k units) Table 223. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country (2021-2026) Table 224. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2027-2032) & (k units) Table 225. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share Forecast by Country (2027-2032) Table 226. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 227. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2021-2026) & (US$ Million) Table 228. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Country (2021-2026) Table 229. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 230. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share Forecast by Country (2027-2032) Table 231. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 232. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026) & (k units) Table 233. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country (2021-2026) Table 234. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2027-2032) & (k units) Table 235. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share Forecast by Country (2027-2032) Table 236. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 237. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2021-2026) & (US$ Million) Table 238. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Country (2021-2026) Table 239. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 240. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share Forecast by Country (2027-2032) Table 241. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 242. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026) & (k units) Table 243. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country (2021-2026) Table 244. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2027-2032) & (k units) Table 245. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share Forecast by Country (2027-2032) Table 246. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 247. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2021-2026) & (US$ Million) Table 248. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Country (2021-2026) Table 249. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 250. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share Forecast by Country (2027-2032) Table 251. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 252. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026) & (k units) Table 253. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country (2021-2026) Table 254. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2027-2032) & (k units) Table 255. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share Forecast by Country (2027-2032) Table 256. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 257. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2021-2026) & (US$ Million) Table 258. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Country (2021-2026) Table 259. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 260. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share Forecast by Country (2027-2032) Table 261. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 262. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026) & (k units) Table 263. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country (2021-2026) Table 264. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2027-2032) & (k units) Table 265. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share Forecast by Country (2027-2032) Table 266. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 267. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2021-2026) & (US$ Million) Table 268. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Country (2021-2026) Table 269. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 270. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share Forecast by Country (2027-2032) Table 271. Key Raw Materials Table 272. Raw Materials Key Suppliers Table 273. First in Class (FIC) Antibody Drug Conjugate (ADC) Distributors List Table 274. First in Class (FIC) Antibody Drug Conjugate (ADC) Customers List Table 275. Research Programs/Design for This Report Table 276. Authors List of This Report Table 277. Secondary Sources Table 278. Primary Sources List of Figures Figure 1. First in Class (FIC) Antibody Drug Conjugate (ADC) Image Figure 2. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (2021-2032) & (US$ Million) Figure 4. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (2021-2032) & (k units) Figure 5. Small Molecule FIC Drugs Image Figure 6. Global Small Molecule FIC Drugs Sales YoY Growth (2021-2032) & (k units) Figure 7. Large Molecule FIC Drugs Image Figure 8. Global Large Molecule FIC Drugs Sales YoY Growth (2021-2032) & (k units) Figure 9. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Type 2025 VS 2032 Figure 11. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Volume by Type in 2025 Figure 12. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Value by Type in 2025 Figure 13. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Volume by Type in 2025 Figure 14. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Value by Type in 2025 Figure 17. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Volume by Type in 2025 Figure 18. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 First in Class (FIC) Antibody Drug Conjugate (ADC) Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Tumors and Cancers Image Figure 24. Global Tumors and Cancers Sales YoY Growth (2021-2032) & (k units) Figure 25. Others Image Figure 26. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 27. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Application 2025 VS 2032 Figure 29. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Volume by Application in 2025 Figure 30. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Value by Application in 2025 Figure 31. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Volume by Application in 2025 Figure 32. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Value by Application in 2025 Figure 35. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Volume by Application in 2025 Figure 36. Latin America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share in Value by Application in 2025 Figure 39. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 40. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Country: 2021

Scope & coverage.

Types
  • Small Molecule FIC Drugs
  • Large Molecule FIC Drugs
Applications
  • Tumors and Cancers
  • Others
Companies covered
  • Arvinas
  • Bayer Corporation
  • Bicara Therapeutics
  • Fabhalta
  • Immatics
  • Litfulo
  • Lytgobi
  • Merus
  • Ogsiveo
  • Pumis Biotechnology (BioNTech)
  • Regeneron Pharmaceuticals
  • Skyclary
  • Talvey
  • Telix
  • Truqap
  • Vertex Pharmaceuticals
  • AstraZeneca
  • Dizal Pharma
  • Shanghai Henlius Biotech, Inc.
  • GSK
  • Jiangsu Hengrui Medicine
  • Pfizer
  • Akeso, Inc
  • Lixin Pharmaceutical Technology
  • Johnson & Johnson
  • Beijing Hotgen Biotech
  • Suzhou Yilian Biopharmaceutical
  • Shenzhen Yipusheng
  • Foreseen Biotechnology
  • Suzhou Zejing Biopharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Estimates and Forecasts (2021-2032)
  5. 1.3 First in Class (FIC) Antibody Drug Conjugate (ADC) Market by Type
  6. 1.3.1 Small Molecule FIC Drugs
  7. 1.3.2 Large Molecule FIC Drugs
  8. 1.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Type
  9. 1.4.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Trends
  2. 2.2 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Drivers
  3. 2.3 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Opportunities and Challenges
  4. 2.4 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (2021-2026)
  2. 3.2 Global Top Players by First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (2021-2026)
  3. 3.3 Global Top Players by First in Class (FIC) Antibody Drug Conjugate (ADC) Price (2021-2026)
  4. 3.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Major Company Production Sites & Headquarters
  6. 3.6 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Company, Product Type & Application
  7. 3.7 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 First in Class (FIC) Antibody Drug Conjugate (ADC) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 First in Class (FIC) Antibody Drug Conjugate (ADC) Tier 1, Tier 2, and Tier 3
4 First in Class (FIC) Antibody Drug Conjugate (ADC) Regional Status and Outlook
  1. 4.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Historic Market Size by Region
  3. 4.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales in Value by Region (2021-2026)
  5. 4.2.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Forecasted Market Size by Region
  7. 4.3.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales in Value by Region (2027-2032)
  9. 4.3.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 First in Class (FIC) Antibody Drug Conjugate (ADC) by Application
  1. 5.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Market by Application
  2. 5.1.1 Tumors and Cancers
  3. 5.1.2 Others
  4. 5.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Application
  5. 5.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Arvinas
  2. 6.1.1 Arvinas Company Information
  3. 6.1.2 Arvinas Business Overview
  4. 6.1.3 Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  6. 6.1.5 Arvinas Recent Developments
  7. 6.2 Bayer Corporation
  8. 6.2.1 Bayer Corporation Company Information
  9. 6.2.2 Bayer Corporation Business Overview
  10. 6.2.3 Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  12. 6.2.5 Bayer Corporation Recent Developments
  13. 6.3 Bicara Therapeutics
  14. 6.3.1 Bicara Therapeutics Company Information
  15. 6.3.2 Bicara Therapeutics Business Overview
  16. 6.3.3 Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  18. 6.3.5 Bicara Therapeutics Recent Developments
  19. 6.4 Fabhalta
  20. 6.4.1 Fabhalta Company Information
  21. 6.4.2 Fabhalta Business Overview
  22. 6.4.3 Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  24. 6.4.5 Fabhalta Recent Developments
  25. 6.5 Immatics
  26. 6.5.1 Immatics Company Information
  27. 6.5.2 Immatics Business Overview
  28. 6.5.3 Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  30. 6.5.5 Immatics Recent Developments
  31. 6.6 Litfulo
  32. 6.6.1 Litfulo Company Information
  33. 6.6.2 Litfulo Business Overview
  34. 6.6.3 Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  36. 6.6.5 Litfulo Recent Developments
  37. 6.7 Lytgobi
  38. 6.7.1 Lytgobi Company Information
  39. 6.7.2 Lytgobi Business Overview
  40. 6.7.3 Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  42. 6.7.5 Lytgobi Recent Developments
  43. 6.8 Merus
  44. 6.8.1 Merus Company Information
  45. 6.8.2 Merus Business Overview
  46. 6.8.3 Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  48. 6.8.5 Merus Recent Developments
  49. 6.9 Ogsiveo
  50. 6.9.1 Ogsiveo Company Information
  51. 6.9.2 Ogsiveo Business Overview
  52. 6.9.3 Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  54. 6.9.5 Ogsiveo Recent Developments
  55. 6.10 Pumis Biotechnology (BioNTech)
  56. 6.10.1 Pumis Biotechnology (BioNTech) Company Information
  57. 6.10.2 Pumis Biotechnology (BioNTech) Business Overview
  58. 6.10.3 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  60. 6.10.5 Pumis Biotechnology (BioNTech) Recent Developments
  61. 6.11 Regeneron Pharmaceuticals
  62. 6.11.1 Regeneron Pharmaceuticals Company Information
  63. 6.11.2 Regeneron Pharmaceuticals Business Overview
  64. 6.11.3 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  66. 6.11.5 Regeneron Pharmaceuticals Recent Developments
  67. 6.12 Skyclary
  68. 6.12.1 Skyclary Company Information
  69. 6.12.2 Skyclary Business Overview
  70. 6.12.3 Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  72. 6.12.5 Skyclary Recent Developments
  73. 6.13 Talvey
  74. 6.13.1 Talvey Company Information
  75. 6.13.2 Talvey Business Overview
  76. 6.13.3 Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  78. 6.13.5 Talvey Recent Developments
  79. 6.14 Telix
  80. 6.14.1 Telix Company Information
  81. 6.14.2 Telix Business Overview
  82. 6.14.3 Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  84. 6.14.5 Telix Recent Developments
  85. 6.15 Truqap
  86. 6.15.1 Truqap Company Information
  87. 6.15.2 Truqap Business Overview
  88. 6.15.3 Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  90. 6.15.5 Truqap Recent Developments
  91. 6.16 Vertex Pharmaceuticals
  92. 6.16.1 Vertex Pharmaceuticals Company Information
  93. 6.16.2 Vertex Pharmaceuticals Business Overview
  94. 6.16.3 Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  96. 6.16.5 Vertex Pharmaceuticals Recent Developments
  97. 6.17 AstraZeneca
  98. 6.17.1 AstraZeneca Company Information
  99. 6.17.2 AstraZeneca Business Overview
  100. 6.17.3 AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  102. 6.17.5 AstraZeneca Recent Developments
  103. 6.18 Dizal Pharma
  104. 6.18.1 Dizal Pharma Company Information
  105. 6.18.2 Dizal Pharma Business Overview
  106. 6.18.3 Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  108. 6.18.5 Dizal Pharma Recent Developments
  109. 6.19 Shanghai Henlius Biotech, Inc.
  110. 6.19.1 Shanghai Henlius Biotech, Inc. Company Information
  111. 6.19.2 Shanghai Henlius Biotech, Inc. Business Overview
  112. 6.19.3 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  114. 6.19.5 Shanghai Henlius Biotech, Inc. Recent Developments
  115. 6.20 GSK
  116. 6.20.1 GSK Company Information
  117. 6.20.2 GSK Business Overview
  118. 6.20.3 GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  120. 6.20.5 GSK Recent Developments
  121. 6.21 Jiangsu Hengrui Medicine
  122. 6.21.1 Jiangsu Hengrui Medicine Company Information
  123. 6.21.2 Jiangsu Hengrui Medicine Business Overview
  124. 6.21.3 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  126. 6.21.5 Jiangsu Hengrui Medicine Recent Developments
  127. 6.22 Pfizer
  128. 6.22.1 Pfizer Company Information
  129. 6.22.2 Pfizer Business Overview
  130. 6.22.3 Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  132. 6.22.5 Pfizer Recent Developments
  133. 6.23 Akeso, Inc
  134. 6.23.1 Akeso, Inc Company Information
  135. 6.23.2 Akeso, Inc Business Overview
  136. 6.23.3 Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  138. 6.23.5 Akeso, Inc Recent Developments
  139. 6.24 Lixin Pharmaceutical Technology
  140. 6.24.1 Lixin Pharmaceutical Technology Company Information
  141. 6.24.2 Lixin Pharmaceutical Technology Business Overview
  142. 6.24.3 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  144. 6.24.5 Lixin Pharmaceutical Technology Recent Developments
  145. 6.25 Johnson & Johnson
  146. 6.25.1 Johnson & Johnson Company Information
  147. 6.25.2 Johnson & Johnson Business Overview
  148. 6.25.3 Johnson & Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  149. 6.25.4 Johnson & Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  150. 6.25.5 Johnson & Johnson Recent Developments
  151. 6.26 Beijing Hotgen Biotech
  152. 6.26.1 Beijing Hotgen Biotech Company Information
  153. 6.26.2 Beijing Hotgen Biotech Business Overview
  154. 6.26.3 Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  155. 6.26.4 Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  156. 6.26.5 Beijing Hotgen Biotech Recent Developments
  157. 6.27 Suzhou Yilian Biopharmaceutical
  158. 6.27.1 Suzhou Yilian Biopharmaceutical Company Information
  159. 6.27.2 Suzhou Yilian Biopharmaceutical Business Overview
  160. 6.27.3 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  161. 6.27.4 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  162. 6.27.5 Suzhou Yilian Biopharmaceutical Recent Developments
  163. 6.28 Shenzhen Yipusheng
  164. 6.28.1 Shenzhen Yipusheng Company Information
  165. 6.28.2 Shenzhen Yipusheng Business Overview
  166. 6.28.3 Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  167. 6.28.4 Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  168. 6.28.5 Shenzhen Yipusheng Recent Developments
  169. 6.29 Foreseen Biotechnology
  170. 6.29.1 Foreseen Biotechnology Company Information
  171. 6.29.2 Foreseen Biotechnology Business Overview
  172. 6.29.3 Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  173. 6.29.4 Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  174. 6.29.5 Foreseen Biotechnology Recent Developments
  175. 6.30 Suzhou Zejing Biopharmaceutical
  176. 6.30.1 Suzhou Zejing Biopharmaceutical Company Information
  177. 6.30.2 Suzhou Zejing Biopharmaceutical Business Overview
  178. 6.30.3 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales, Revenue and Gross Margin (2021-2026)
  179. 6.30.4 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Portfolio
  180. 6.30.5 Suzhou Zejing Biopharmaceutical Recent Developments
7 North America by Country
  1. 7.1 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country
  2. 7.1.1 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026)
  4. 7.1.3 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2027-2032)
  5. 7.2 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country
  6. 7.2.1 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2021-2026)
  8. 7.2.3 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country
  2. 8.1.1 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026)
  4. 8.1.3 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2027-2032)
  5. 8.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country
  6. 8.2.1 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2021-2026)
  8. 8.2.3 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country
  2. 9.1.1 Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country
  6. 9.2.1 Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country
  2. 10.1.1 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026)
  4. 10.1.3 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2027-2032)
  5. 10.2 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country
  6. 10.2.1 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2021-2026)
  8. 10.2.3 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country
  2. 11.1.1 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country
  6. 11.2.1 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Value Chain Analysis
  2. 12.1.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 First in Class (FIC) Antibody Drug Conjugate (ADC) Production Mode & Process
  7. 12.2 First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 First in Class (FIC) Antibody Drug Conjugate (ADC) Distributors
  10. 12.2.3 First in Class (FIC) Antibody Drug Conjugate (ADC) Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst